WITHDRAWN: Maresin-1 promotes mitochondrial function and autophagy after myocardial I/R injury by modulating the SIRT1/NRF2 signaling

Abstract

Maresin-1 (MaR1) is a derived metabolite of Docosahexaenoic acid (DHA) and has been proved to play a protective role in ischemic reperfusion (I/R) damage. Nevertheless, the role and potential mechanism of MaR1 in myocardial ischemic reperfusion injury (MIRI) remain obscure. In this study, hypoxia-reoxygenation (H/R) cell model was established by hypoxia treatment. CCK-8, western blot and flow cytometry were used to estimate cell proliferation and apoptosis. LDH, CK-MB and inflammation factors were detected by corresponding kits. Mitochondrial function impairment was estimated through ROS, ATP, mPTP, OCR and JC-1 staining and DCFH-DA staining. Monodansylcadaverine (MDC) staining and western blot were carried out to identify the autophagy. In addition, the SIRT1/NRF2 signaling was estimated with western blot. The data showed that MaR1 pretreatment elevated cell viability, reduced the contents of LDH, CK-MB, and inflammation factors after H/R treatment. In addition, MaR1 mitigated the functional damage of mitochondria, ameliorated H/R-induced abnormal level of autophagy and hindered the cell apoptosis rate. MaR1 also declined the contents of pro-apoptotic proteins, and inhibited oxidative stress in H/R-challenged H9c2 cells. Meanwhile, the contents of Nuclear Nrf2, Nrf2 and SIRT1 were enhanced following MaR1 treatment. SIRT1 inhibitor Selisistat (EX-527) reversed the protective influences of MaR1 on H/R-induced H9c2 cells. To sum up, MaR1 may ameliorate H/R-stimulated H9c2 cell injury via the modulation of SIRT1/NRF2 signaling.